Literature DB >> 10064255

Fluoroquinolone toxicity profiles: a review focusing on newer agents.

B A Lipsky1, C A Baker.   

Abstract

For 2 decades fluoroquinolones have been found to be generally well-tolerated and safe. Adverse events may be inherent to the class or influenced by structural modifications. The commonest adverse events are gastrointestinal tract (GI) and central nervous system (CNS) reactions; nephrotoxicity and tendinitis are infrequent, but agents differ greatly in phototoxic potential. Fluoroquinolones are safe in elderly, human immunodeficiency virus-infected, and neutropenic patients, but because of possible effects on articular cartilage, they are not currently recommended for children or pregnant women. Four new agents have recently been licensed. Levofloxacin causes few GI or CNS adverse events and is minimally phototoxic. Sparfloxacin infrequently causes GI or CNS effects but is associated with relatively high rates of phototoxicity and prolongation of the electrocardiographic QTc interval (Q-T interval, corrected for heart rate). Grepafloxacin causes relatively high rates of GI effects, taste perversion, and QTc interval prolongation, but it is minimally phototoxic. Trovafloxacin is associated with a moderate rate of GI effects and a relatively high incidence of dizziness but has low phototoxic potential.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10064255     DOI: 10.1086/515104

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  76 in total

1.  In vitro activities of three nonfluorinated quinolones against representative bacterial isolates.

Authors:  A L Barry; P C Fuchs; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 2.  Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?

Authors:  Paul J Converse; Eric L Nuermberger; Deepak V Almeida; Jacques H Grosset
Journal:  Future Microbiol       Date:  2011-10       Impact factor: 3.165

3.  Acute renal failure probably induced by prulifloxacin in an elderly woman : a first case report.

Authors:  L Gallelli; A Gallelli; G Vero; F Roccia; G Pelaia; G De Sarro; R Maselli
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

4.  Adverse reactions induced by NSAIDs and antibacterials: analysis of spontaneous reports from the Sicilian regional database.

Authors:  Giovanni Polimeni; Francesco Salvo; Paola Cutroneo; Ilaria Morreale; Achille Patrizio Caputi
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

5.  Mirtazapine therapy for dysgeusia in an elderly patient.

Authors:  Kalpana P Padala; Cheryl K Hinners; Prasad R Padala
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

6.  Lack of effect of DX-619, a novel des-fluoro(6)-quinolone, on glomerular filtration rate measured by serum clearance of cold iohexol.

Authors:  Nenad Sarapa; Prachi Wickremasingha; Nanxiang Ge; Richard Weitzman; Merynda Fuellhart; Cindy Yen; Julia Lloyd-Parks
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

7.  Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis.

Authors:  Tina Papastavros; Lisa R Dolovich; Anne Holbrook; Lori Whitehead; Mark Loeb
Journal:  CMAJ       Date:  2002-07-23       Impact factor: 8.262

Review 8.  Diagnosis and treatment of allergic rhinitis and sinusitis during pregnancy and lactation.

Authors:  Gary A Incaudo
Journal:  Clin Rev Allergy Immunol       Date:  2004-10       Impact factor: 8.667

Review 9.  Fluoroquinolones in the elderly: safety considerations.

Authors:  Ralf Stahlmann; Hartmut Lode
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three italian regions.

Authors:  Roberto Leone; Mauro Venegoni; Domenico Motola; Ugo Moretti; Valentina Piazzetta; Alfredo Cocci; Domenico Resi; Federico Mozzo; Giampaolo Velo; Liliana Burzilleri; Nicola Montanaro; Anita Conforti
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.